Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02722538
Other study ID # TAR-200-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 31, 2016
Est. completion date May 2, 2019

Study information

Verified date September 2023
Source Taris Biomedical LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date May 2, 2019
Est. primary completion date May 2, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological proof of muscle-invasive transitional cell carcinoma of the bladder (stage II-III). Subjects with evidence of metastatic nodal disease to the obuturator or presacral lymph nodes only may be included (N1 M0). Subjects with any degree of fixation of the pelvic sidewall are not eligible. - In Arm 1, subjects must have residual visible tumor following TURBT. In Arm 2, subjects must be fully resected (i.e., no visible tumor or as little tumor as possible) after restaging TURBT 2-6 weeks prior to Study Day 0. - Adequate bone marrow, liver, and renal function, as assessed by the following requirements conducted within 21 days prior to dosing: 1. Hemoglobin = 9.0 g/dL 2. Absolute neutrophil count (ANC) = 1,500/mm3 3. Platelet count = 100,000/mm3 4. Total bilirubin = 1.5xULN (upper limit of normal) 5. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5xULN 6. Glomerular Filtration Rate (GFR) = 30% (= 30 ml/min/1.73 m2) - Subjects must be willing to undergo a cystoscopy on study for investigational product removal. - Eligible for and willing to undergo RC per the attending urologist. - Subjects must be deemed ineligible for cisplatin-based combination chemotherapy by the attending medical oncologist. - Subjects medically eligible for neoadjuvant cisplatin-based combination chemotherapy who refuse this therapeutic option and understand the risks and benefits of doing so. - Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder. - Written informed consent and Health Insurance Portability and Accountability Act of 1966 (HIPAA) authorization for release of personal health information. - Age > 18 years at the time of consent. Exclusion Criteria: - Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome. - Prior systemic chemotherapy for transitional cell carcinoma of the bladder. Any other prior systemic chemotherapy for a non-urothelial carcinoma must have been completed > 5 years prior to initiation of study. - Previous exposure to gemcitabine instillations. - Currently receiving other intravesical chemotherapy. - Concurrent clinically significant infections as determined by the treating investigator. - Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe placement, indwelling use or removal of TAR-200. - Documented history of vesicoureteral reflux or the presence of an indwelling ureteral stent or nephrostomy tube at the time of screening. - Pelvic radiotherapy administered within less than 6 months prior to enrollment. Subjects who received radiotherapy = 6 months prior to enrollment must demonstrate no cystoscopic evidence or symptoms of radiation cystitis. - Bladder Post-Void Residual Volume (PVR) of > 250-mL. - Active, uncontrolled urogenital bacterial, viral or fungal infections, including urinary tract infection that in the opinion of the investigator, contraindicates participation. Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study. - History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation. - History of diagnosis of neurogenic bladder. - Concomitant immunosuppressive medications, such as methotrexate or TNF inhibitors, within 2 weeks of Study Day 0, exclusive of steroid doses = 5 mg daily. - Difficulty providing blood samples. - Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up. - Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.

Locations

Country Name City State
Netherlands Radboudumc Nijmegen
United States Johns Hopkins Hospital Baltimore Maryland
United States University of Chicago Medical Center Chicago Illinois
United States Ohio State University Wexner Medical Center Columbus Ohio
United States University of Southern California Norris Comprehensive Cancer Center Los Angeles California
United States Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Taris Biomedical LLC

Countries where clinical trial is conducted

United States,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0 Maximum 132 days
Secondary Number of participants who are tolerant of TAR-200 indwelling From Day 0 up to Day 7
Secondary Percentage of participants who are tolerant of TAR-200 indwelling From Day 0 up to Day 7
Secondary Number of participants who are tolerant of TAR-200 indwelling From Day 21 up to Day 28
Secondary Percentage of participants who are tolerant of TAR-200 indwelling From Day 21 up to Day 28
Secondary Cmax, plasma dFdU Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in plasma. From Day 0 up to Day 28
Secondary Tmax, plasma dFdU Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in plasma. From Day 0 up to Day 28
Secondary Cavg, plasma dFdU Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in plasma From Day 0 up to Day 28
Secondary Cmax, plasma dFdC Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma From Day 0 up to Day 28
Secondary Tmax, plasma dFdC Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma From Day 0 up to Day 28
Secondary Cavg, plasma dFdC Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma From Day 0 up to Day 28
Secondary Cmax, urine dFdU (Arm 1 only) Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine From Day 0 up to Day 28
Secondary Tmax, urine dFdU (Arm 1 only) Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine From Day 0 up to Day 28
Secondary Cavg, urine dFdU (Arm 1 only) Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in urine From Day 0 up to Day 28
Secondary Cmax, urine dFdC (Arm 1 only) Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine From Day 0 up to Day 28
Secondary Tmax, urine dFdC (Arm 1 only) Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine From Day 0 up to Day 28
Secondary Cavg, urine dFdC (Arm 1 only) Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine. From Day 0 up to Day 28
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (AKT) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD31) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (Ki67) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (TUNEL) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD4) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD8) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (PD-L1) (Arm 1) Anti-tumor analysis will occur at study visit Day 28.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (AKT) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD31) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (Ki67) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (TUNEL) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD4) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (CD8) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
Secondary Preliminary anti-tumor effects assessed in tumor material (post-treatment) for immunohistochemical tissue biomarkers of drug-induced cell death (PD-L1) (Arm 2) Anti-tumor analysis will occur at study visit Day 42.
See also
  Status Clinical Trial Phase
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn NCT05335707 - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed NCT03998579 - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer N/A
Not yet recruiting NCT04525781 - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Recruiting NCT05822934 - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Phase 3
Completed NCT06156787 - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 1
Completed NCT02139371 - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 0
Completed NCT03433924 - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Completed NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Phase 2
Recruiting NCT05621837 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting NCT05644041 - Intravesical Gemcitabine in Patients With NMIBC Phase 2
Completed NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute N/A
Recruiting NCT04861584 - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Phase 2
Completed NCT01836978 - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy N/A
Terminated NCT01374789 - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer Phase 2
Recruiting NCT03844256 - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/Phase 2